In states that covered obesity-labeled GLP-1 RAs, total GLP-1 RA use rose less than obesity-labeled use alone, suggesting possible substitution.
|Articles|June 8, 2011
AMCP 2011: Interview with Dr. Jeffrey Dunn of SelectHealth, Salt Lake City, Utah
Dr. Jeffrey Dunn shares his opinion on how healthcare reform issues, such as Comparative Effectiveness Research, will impact formulary management.
Advertisement
Dr. Jeffrey Dunn, Formulary and Contract Manager at SelectHealth in Salt Lake City, Utah, discusses healthcare reform issues with a focus on Comparative Effectiveness Research (CER).
Advertisement
Related to this article
HR 1 brings Medicaid work requirements and narrower immigrant eligibility by January 2027, and CBO projects 10 million more uninsured by 2034.
CMS ends ACA subsidies for 189,000 enrollees with duplicate Medicare, Medicaid, or CHIP coverage or listed as deceased, with a 30-day dispute window.
Advertisement
Advertisement
Trending on AJMC
1
PBM Reform and Supportive Care Needs: Nicolas Ferreyros
2
5 Things to Know About the One Big Beautiful Bill Act
3
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
4
Genetic Analysis Links Insomnia Liability to Higher Inflammation Marker
5